跳转至内容
Merck
CN
登录查看公司和协议定价

About This Item

UNSPSC代码:
12352202
NACRES:
NA.32
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

生物来源

human

重组

expressed in HEK 293 cells

方案

≥95% (HPLC)
≥95% (SDS-PAGE)

表单

lyophilized

分子量

20.0-22.0 kDa

包装

pkg of 10 μg

技术

cell culture | mammalian: suitable

杂质

<0.1 EU/μg endotoxin, tested

颜色

white

UniProt登记号

运输

wet ice

储存温度

−20°C

基因信息

human ... FIGF(2277)

一般描述

VEGFD (vascular endothelial growth factor D), or c-fos-induced growth factor, is a member of the VEGF family of growth factors, and is composed of VEGF-homology domain, receptor binding domains, and pro-peptides in both terminals. It is secreted in the extracellular space in a full length form with both C- and N-terminal pro-peptides, which are cleaved off to produce the mature VEGFD form. It is an angiogenesis-related factor.
Recombinant human VEGF-D is a 26.2 kDa non-disulfide linked homodimeric protein consisting of two 117 amino acid polypeptide chains. Due to glycosylation the protein migrates as a 20.0-22.0 kDa band under non-reducing condition.

应用

VEGFD (vascular endothelial growth factor D) human has been used in for the treatment of buffalo luteal cell culture to determine the effect of VEGFD on the expression of lymphatic endothelial marker (LYVE1), thereby investigating the role of VEGFD in luteal lymphangeogenesis during different stages of estrous cycle.

生化/生理作用

Mature VEGFD (vascular endothelial growth factor D) interacts with VEGFR-3, a tyrosine kinase receptor, with high affinity. This receptor predominantly resides on adult lymphatic endothelium and participates in lymphangiogenesis. VEGFD also interacts with Nrp-2 (neuropilin), a non-tyrosine kinase receptor, which functions as a lymphangiogenesis-associated factor. This factor promotes tumor lymphangiogenesis and hence, lymph node metastasis in various cancers, such as ovarian cancer. In patients with CRC (colorectal cancer), higher expression of VEGFD is linked with resistance to bevacizumab, and has potential as a biomarker for predicting the benefit of bevacizumab in CRC chemotherapy.

序列

FAATFYDIET LKVIDEEWQR TQCSPRETCV EVASELGKST NTFFKPPCVN VFRCGGCCNE ESLICMNTST SYISKQLFEI SVPLTSVPEL VPVKVANHTG CKCLPTAPRH PYSIIRR

外形

Lyophilized with no additives.

制备说明

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持